NOVAVAX INC Deferred Revenue
NOVAVAX INC (NVAX) had Deferred Revenue of $49.40 million as of 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2025-05-08
- 2025-03-31: Deferred Revenue $49.40M.
- 2024-09-30: Deferred Revenue $70.00M.
- 2024-06-30: Deferred Revenue $109.20M.
- 2021-12-31: Deferred Revenue $1.60B.
| Period end | Deferred Revenue |
|---|---|
| 2025-03-31 | $49.40M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $70.00M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $109.20M 10-Q · filed 2024-08-08 |
| 2021-12-31 | $1.60B 10-K · filed 2022-03-01 |
| 2020-12-31 | $45.00M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |